Inflarx (NASDAQ:IFRX) Upgraded to Hold at Zacks Investment Research


Zacks Investment Research upgraded shares of Inflarx (NASDAQ:IFRX) from a sell rating to a hold rating in a research note released on Wednesday, July 18th.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

Other equities research analysts have also recently issued reports about the company. Leerink Swann increased their price target on Inflarx from $31.00 to $36.00 and gave the company an outperform rating in a research note on Monday, April 2nd. Raymond James initiated coverage on Inflarx in a research note on Thursday, June 28th. They issued an outperform rating and a $44.00 price target for the company. SunTrust Banks initiated coverage on Inflarx in a research note on Thursday, June 28th. They issued a buy rating and a $55.00 price objective for the company. ValuEngine upgraded Inflarx from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Finally, BMO Capital Markets initiated coverage on Inflarx in a research note on Friday, July 13th. They issued an outperform rating and a $45.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $42.67.

IFRX stock traded up $0.42 during trading on Wednesday, reaching $31.05. 7,940 shares of the company traded hands, compared to its average volume of 12,233. Inflarx has a 12 month low of $14.47 and a 12 month high of $42.83. The company has a market cap of $724.77 million and a P/E ratio of -10.56.

Inflarx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.24. sell-side analysts predict that Inflarx will post -1.66 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in IFRX. Amundi Pioneer Asset Management Inc. purchased a new position in Inflarx during the fourth quarter valued at approximately $126,000. Barclays PLC acquired a new stake in Inflarx in the first quarter valued at approximately $144,000. Northern Trust Corp acquired a new stake in Inflarx in the first quarter valued at approximately $228,000. Schwab Charles Investment Management Inc. acquired a new stake in Inflarx in the first quarter valued at approximately $367,000. Finally, Birchview Capital LP acquired a new stake in Inflarx in the second quarter valued at approximately $516,000. Institutional investors own 41.80% of the company’s stock.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

See Also: What does relative strength index mean?

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *